Bioventus Inc. (NASDAQ: BVS) Stock Competitors & Peer Comparison
See BVS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BVS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BVS | $14.29 | -2.66% | 970.8M | 18.86 | $0.76 | N/A |
| ABT | $116.24 | +1.58% | 197.7B | 21.93 | $5.21 | +2.16% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $331.94 | -2.36% | 125.6B | 24.48 | $13.39 | +1.05% |
| MDT | $92.86 | -1.35% | 118.2B | 16.70 | $5.53 | +3.08% |
| BSX | $50.62 | -2.67% | 73.4B | 15.93 | $3.10 | N/A |
| EW | $89.83 | -2.66% | 51.7B | 33.26 | $2.70 | N/A |
| DXCM | $91.65 | +1.97% | 34B | 38.72 | $2.33 | N/A |
| RMD | $233.10 | +1.35% | 33.1B | 21.22 | $10.77 | +1.07% |
| PHG | $27.47 | +1.35% | 27B | 15.78 | $1.75 | +3.59% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BVS vs ABT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ABT has a market cap of 197.7B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ABT trades at $116.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ABT's P/E ratio is 21.93. In terms of profitability, BVS's ROE is +0.28%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BVS is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BVS vs BSX-PA Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BVS's ROE is +0.28%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BVS is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
BVS vs SYK Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SYK has a market cap of 125.6B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SYK trades at $331.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SYK's P/E ratio is 24.48. In terms of profitability, BVS's ROE is +0.28%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BVS is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SYK's competition here
Medtronic plc (NYSE: MDT)
BVS vs MDT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, MDT has a market cap of 118.2B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while MDT trades at $92.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas MDT's P/E ratio is 16.70. In terms of profitability, BVS's ROE is +0.28%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BVS is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
BVS vs BSX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BSX has a market cap of 73.4B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BSX trades at $50.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BSX's P/E ratio is 15.93. In terms of profitability, BVS's ROE is +0.28%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BVS is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BVS vs EW Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while EW trades at $89.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas EW's P/E ratio is 33.26. In terms of profitability, BVS's ROE is +0.28%, compared to EW's ROE of +0.10%. Regarding short-term risk, BVS is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for BVS.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
BVS vs DXCM Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, DXCM has a market cap of 34B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while DXCM trades at $91.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas DXCM's P/E ratio is 38.72. In terms of profitability, BVS's ROE is +0.28%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BVS is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BVS.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
BVS vs RMD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, RMD has a market cap of 33.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while RMD trades at $233.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas RMD's P/E ratio is 21.22. In terms of profitability, BVS's ROE is +0.28%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BVS is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BVS vs PHG Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, PHG has a market cap of 27B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while PHG trades at $27.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas PHG's P/E ratio is 15.78. In terms of profitability, BVS's ROE is +0.28%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BVS is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for BVS.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BVS vs ZBH Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ZBH has a market cap of 19.2B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ZBH trades at $100.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ZBH's P/E ratio is 11.68. In terms of profitability, BVS's ROE is +0.28%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BVS is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BVS vs ABMD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BVS's ROE is +0.28%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BVS is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
BVS vs PEN Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while PEN trades at $325.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas PEN's P/E ratio is 84.57. In terms of profitability, BVS's ROE is +0.28%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BVS is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BVS.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BVS vs SWAV Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BVS's ROE is +0.28%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BVS is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
BVS vs SNN Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SNN has a market cap of 12.2B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SNN trades at $29.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SNN's P/E ratio is 13.66. In terms of profitability, BVS's ROE is +0.28%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BVS is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SNN's competition here
Globus Medical, Inc. (NYSE: GMED)
BVS vs GMED Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while GMED trades at $86.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas GMED's P/E ratio is 19.30. In terms of profitability, BVS's ROE is +0.28%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BVS is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for BVS.Check GMED's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BVS vs ALGN Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ALGN trades at $160.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ALGN's P/E ratio is 14.49. In terms of profitability, BVS's ROE is +0.28%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, BVS is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ALGN's competition here
Glaukos Corporation (NYSE: GKOS)
BVS vs GKOS Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, GKOS has a market cap of 10.9B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while GKOS trades at $186.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas GKOS's P/E ratio is -214.73. In terms of profitability, BVS's ROE is +0.28%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BVS is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BVS.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
BVS vs PODD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, PODD has a market cap of 10.5B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while PODD trades at $149.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas PODD's P/E ratio is 25.81. In terms of profitability, BVS's ROE is +0.28%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BVS is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BVS vs BIO Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BIO has a market cap of 10.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BIO trades at $381.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BIO's P/E ratio is 40.57. In terms of profitability, BVS's ROE is +0.28%, compared to BIO's ROE of +0.03%. Regarding short-term risk, BVS is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
BVS vs BIO-B Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BIO-B has a market cap of 10B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BIO-B trades at $365.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BIO-B's P/E ratio is -64.28. In terms of profitability, BVS's ROE is +0.28%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, BVS is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for BVS.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
BVS vs MASI Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas MASI's P/E ratio is 44.43. In terms of profitability, BVS's ROE is +0.28%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BVS is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BVS.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BVS vs BRKR Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BRKR trades at $59.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BRKR's P/E ratio is 30.11. In terms of profitability, BVS's ROE is +0.28%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BVS is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BRKR's competition here
Haemonetics Corporation (NYSE: HAE)
BVS vs HAE Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while HAE trades at $108.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas HAE's P/E ratio is 21.59. In terms of profitability, BVS's ROE is +0.28%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BVS is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BVS.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BVS vs NARI Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas NARI's P/E ratio is -59.24. In terms of profitability, BVS's ROE is +0.28%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BVS is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BVS.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
BVS vs LIVN Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while LIVN trades at $78.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas LIVN's P/E ratio is 18.58. In terms of profitability, BVS's ROE is +0.28%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BVS is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BVS.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
BVS vs ITGR Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ITGR trades at $125.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ITGR's P/E ratio is 19.72. In terms of profitability, BVS's ROE is +0.28%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BVS is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BVS vs IRTC Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while IRTC trades at $127.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas IRTC's P/E ratio is -199.97. In terms of profitability, BVS's ROE is +0.28%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BVS is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BVS.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
BVS vs AXNX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BVS's ROE is +0.28%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BVS is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for BVS.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BVS vs TMDX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while TMDX trades at $94.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas TMDX's P/E ratio is 46.12. In terms of profitability, BVS's ROE is +0.28%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BVS is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BVS vs AXGN Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while AXGN trades at $49.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas AXGN's P/E ratio is 122.21. In terms of profitability, BVS's ROE is +0.28%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BVS is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BVS.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BVS vs BFLY Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BFLY trades at $9.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BFLY's P/E ratio is -38.19. In terms of profitability, BVS's ROE is +0.28%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BVS is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BVS vs UFPT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while UFPT trades at $309.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas UFPT's P/E ratio is 31.08. In terms of profitability, BVS's ROE is +0.28%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BVS is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BVS vs ESTA Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ESTA trades at $72.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ESTA's P/E ratio is -56.76. In terms of profitability, BVS's ROE is +0.28%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BVS is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BVS vs NUVA Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BVS's ROE is +0.28%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BVS is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BVS.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
BVS vs NVCR Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while NVCR trades at $17.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas NVCR's P/E ratio is -11.61. In terms of profitability, BVS's ROE is +0.28%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BVS is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BVS.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BVS vs INSP Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while INSP trades at $62.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas INSP's P/E ratio is 26.96. In terms of profitability, BVS's ROE is +0.28%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BVS is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BVS.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BVS vs TNDM Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while TNDM trades at $22.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas TNDM's P/E ratio is -20.52. In terms of profitability, BVS's ROE is +0.28%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BVS is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
BVS vs CNMD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CNMD trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CNMD's P/E ratio is 11.29. In terms of profitability, BVS's ROE is +0.28%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BVS is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CNMD's competition here
Enovis Corporation (NYSE: ENOV)
BVS vs ENOV Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ENOV trades at $26.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ENOV's P/E ratio is 7.50. In terms of profitability, BVS's ROE is +0.28%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BVS is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ENOV's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BVS vs ATEC Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ATEC trades at $9.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ATEC's P/E ratio is -154.83. In terms of profitability, BVS's ROE is +0.28%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BVS is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ATEC's competition here
Artivion, Inc. (NYSE: AORT)
BVS vs AORT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while AORT trades at $28.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas AORT's P/E ratio is 46.60. In terms of profitability, BVS's ROE is +0.28%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BVS is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
BVS vs HSKA Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BVS's ROE is +0.28%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BVS is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BVS.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BVS vs IART Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while IART trades at $16.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas IART's P/E ratio is 7.03. In terms of profitability, BVS's ROE is +0.28%, compared to IART's ROE of -0.01%. Regarding short-term risk, BVS is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BVS.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BVS vs PRCT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while PRCT trades at $21.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas PRCT's P/E ratio is -10.69. In terms of profitability, BVS's ROE is +0.28%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BVS is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BVS vs AVNS Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BVS's ROE is +0.28%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BVS is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BVS.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BVS vs LMRI Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while LMRI trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas LMRI's P/E ratio is -22.73. In terms of profitability, BVS's ROE is +0.28%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BVS is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BVS vs SILK Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SILK's P/E ratio is -18.96. In terms of profitability, BVS's ROE is +0.28%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BVS is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
BVS vs IRMD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while IRMD trades at $86.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas IRMD's P/E ratio is 43.56. In terms of profitability, BVS's ROE is +0.28%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BVS is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
BVS vs FNA Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas FNA's P/E ratio is -19.83. In terms of profitability, BVS's ROE is +0.28%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BVS is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BVS.Check FNA's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BVS vs CBLL Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CBLL has a market cap of 922.4M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CBLL trades at $24.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CBLL's P/E ratio is -14.91. In terms of profitability, BVS's ROE is +0.28%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, BVS is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CBLL's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BVS vs AVR Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, AVR has a market cap of 899.4M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while AVR trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas AVR's P/E ratio is -4.15. In terms of profitability, BVS's ROE is +0.28%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BVS is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BVS.Check AVR's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BVS vs BBNX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BBNX has a market cap of 876.4M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BBNX trades at $19.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BBNX's P/E ratio is -12.90. In terms of profitability, BVS's ROE is +0.28%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BVS is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BBNX's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BVS vs SIBN Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SIBN has a market cap of 863.9M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SIBN trades at $19.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SIBN's P/E ratio is -57.29. In terms of profitability, BVS's ROE is +0.28%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BVS is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
BVS vs INMD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, INMD has a market cap of 857.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while INMD trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas INMD's P/E ratio is 10.36. In terms of profitability, BVS's ROE is +0.28%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BVS is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BVS vs CSII Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CSII's P/E ratio is -20.83. In terms of profitability, BVS's ROE is +0.28%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BVS is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BVS.Check CSII's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BVS vs VREX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, VREX has a market cap of 778.4M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas VREX's P/E ratio is 19.46. In terms of profitability, BVS's ROE is +0.28%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BVS is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BVS.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BVS vs AHCO Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, AHCO has a market cap of 733.3M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while AHCO trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas AHCO's P/E ratio is 11.00. In terms of profitability, BVS's ROE is +0.28%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BVS is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BVS.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BVS vs SSII Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SSII has a market cap of 722.5M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SSII trades at $3.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SSII's P/E ratio is -70.41. In terms of profitability, BVS's ROE is +0.28%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BVS is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BVS vs KIDS Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, KIDS has a market cap of 673.7M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while KIDS trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas KIDS's P/E ratio is -22.23. In terms of profitability, BVS's ROE is +0.28%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BVS is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BVS.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BVS vs SRDX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BVS's ROE is +0.28%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BVS is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BVS vs CTKB Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CTKB has a market cap of 601.8M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CTKB trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CTKB's P/E ratio is -24.69. In terms of profitability, BVS's ROE is +0.28%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BVS is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CTKB's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
BVS vs BWAY Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BWAY has a market cap of 587.2M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BWAY trades at $14.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BWAY's P/E ratio is 38.03. In terms of profitability, BVS's ROE is +0.28%, compared to BWAY's ROE of +0.13%. Regarding short-term risk, BVS is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BWAY's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BVS vs APEN Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas APEN's P/E ratio is -9.43. In terms of profitability, BVS's ROE is +0.28%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BVS is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BVS.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BVS vs DCTH Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, DCTH has a market cap of 578.2M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while DCTH trades at $16.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas DCTH's P/E ratio is 1675.00. In terms of profitability, BVS's ROE is +0.28%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BVS is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BVS.Check DCTH's competition here
Cerus Corporation (NASDAQ: CERS)
BVS vs CERS Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CERS has a market cap of 562.3M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CERS trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CERS's P/E ratio is -55.69. In terms of profitability, BVS's ROE is +0.28%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BVS is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CERS's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BVS vs ZIMV Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BVS's ROE is +0.28%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, BVS is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BVS vs TCMD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, TCMD has a market cap of 528.5M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while TCMD trades at $23.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas TCMD's P/E ratio is 26.63. In terms of profitability, BVS's ROE is +0.28%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BVS is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BVS vs NPCE Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, NPCE has a market cap of 478M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while NPCE trades at $14.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas NPCE's P/E ratio is -24.60. In terms of profitability, BVS's ROE is +0.28%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BVS is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BVS.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BVS vs CLPT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CLPT has a market cap of 455.5M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CLPT trades at $15.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CLPT's P/E ratio is -12.87. In terms of profitability, BVS's ROE is +0.28%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BVS is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CLPT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
BVS vs CARL Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CARL has a market cap of 448.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CARL trades at $16.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CARL's P/E ratio is -11.54. In terms of profitability, BVS's ROE is +0.28%, compared to CARL's ROE of -0.38%. Regarding short-term risk, BVS is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CARL's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BVS vs SGHT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SGHT has a market cap of 443.4M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SGHT trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SGHT's P/E ratio is -14.55. In terms of profitability, BVS's ROE is +0.28%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BVS is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BVS vs OFIX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, OFIX has a market cap of 404.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while OFIX trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas OFIX's P/E ratio is -13.08. In terms of profitability, BVS's ROE is +0.28%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BVS is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check OFIX's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BVS vs PACB Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, PACB has a market cap of 382M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while PACB trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas PACB's P/E ratio is -3.00. In terms of profitability, BVS's ROE is +0.28%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BVS is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BVS.Check PACB's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BVS vs SENS Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SENS has a market cap of 368.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SENS trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SENS's P/E ratio is -4.41. In terms of profitability, BVS's ROE is +0.28%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BVS is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BVS.Check SENS's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BVS vs CATX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CATX has a market cap of 367.2M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CATX trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CATX's P/E ratio is -2.42. In terms of profitability, BVS's ROE is +0.28%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BVS is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CATX's competition here
Picard Medical, Inc. (AMEX: PMI)
BVS vs PMI Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, PMI has a market cap of 333.8M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while PMI trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas PMI's P/E ratio is -2.71. In terms of profitability, BVS's ROE is +0.28%, compared to PMI's ROE of -9.31%. Regarding short-term risk, BVS is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check PMI's competition here
Electromed, Inc. (AMEX: ELMD)
BVS vs ELMD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ELMD has a market cap of 333.1M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ELMD trades at $40.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ELMD's P/E ratio is 34.39. In terms of profitability, BVS's ROE is +0.28%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, BVS is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BVS vs TLSI Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, TLSI has a market cap of 322M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while TLSI trades at $5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas TLSI's P/E ratio is -3.11. In terms of profitability, BVS's ROE is +0.28%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BVS is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TLSI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BVS vs SMLR Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BVS's ROE is +0.28%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, BVS is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BVS.Check SMLR's competition here
CapsoVision, Inc. (NASDAQ: CV)
BVS vs CV Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, CV has a market cap of 295.3M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while CV trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas CV's P/E ratio is -2.36. In terms of profitability, BVS's ROE is +0.28%, compared to CV's ROE of -1.78%. Regarding short-term risk, BVS is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BVS.Check CV's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BVS vs TMCI Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, TMCI has a market cap of 289.3M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while TMCI trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas TMCI's P/E ratio is -4.74. In terms of profitability, BVS's ROE is +0.28%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BVS is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check TMCI's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
BVS vs ANIK Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ANIK has a market cap of 285.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ANIK trades at $21.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ANIK's P/E ratio is 43.55. In terms of profitability, BVS's ROE is +0.28%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, BVS is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for BVS.Check ANIK's competition here
RxSight, Inc. (NASDAQ: RXST)
BVS vs RXST Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, RXST has a market cap of 252.1M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while RXST trades at $6.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas RXST's P/E ratio is -6.55. In terms of profitability, BVS's ROE is +0.28%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BVS is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BVS.Check RXST's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BVS vs RCEL Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, RCEL has a market cap of 250.7M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while RCEL trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas RCEL's P/E ratio is -6.43. In terms of profitability, BVS's ROE is +0.28%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BVS is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BVS.Check RCEL's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BVS vs MGRM Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BVS's ROE is +0.28%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, BVS is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BVS.Check MGRM's competition here
Profound Medical Corp. (NASDAQ: PROF)
BVS vs PROF Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, PROF has a market cap of 241.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while PROF trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas PROF's P/E ratio is -5.36. In terms of profitability, BVS's ROE is +0.28%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BVS is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BVS.Check PROF's competition here
Nevro Corp. (NYSE: NVRO)
BVS vs NVRO Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BVS's ROE is +0.28%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BVS is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BVS.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BVS vs STIM Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, STIM has a market cap of 215M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while STIM trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas STIM's P/E ratio is -5.72. In terms of profitability, BVS's ROE is +0.28%, compared to STIM's ROE of -1.51%. Regarding short-term risk, BVS is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BVS.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BVS vs BSGM Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BVS's ROE is +0.28%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, BVS is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BVS.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
BVS vs LUCD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, LUCD has a market cap of 183.2M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas LUCD's P/E ratio is -2.60. In terms of profitability, BVS's ROE is +0.28%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, BVS is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BVS.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BVS vs MDGS Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BVS's ROE is +0.28%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BVS is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BVS.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BVS vs QIPT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BVS's ROE is +0.28%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BVS is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BVS.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BVS vs FOCL Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, FOCL has a market cap of 158.9M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while FOCL trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas FOCL's P/E ratio is -4.10. In terms of profitability, BVS's ROE is +0.28%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, BVS is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BVS.Check FOCL's competition here
Inogen, Inc. (NASDAQ: INGN)
BVS vs INGN Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, INGN has a market cap of 151.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while INGN trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas INGN's P/E ratio is -6.15. In terms of profitability, BVS's ROE is +0.28%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BVS is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for BVS.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BVS vs QTRX Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, QTRX has a market cap of 147M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while QTRX trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas QTRX's P/E ratio is -1.23. In terms of profitability, BVS's ROE is +0.28%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BVS is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BVS.Check QTRX's competition here
Solana Company (NASDAQ: HSDT)
BVS vs HSDT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, HSDT has a market cap of 108.6M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while HSDT trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas HSDT's P/E ratio is -0.02. In terms of profitability, BVS's ROE is +0.28%, compared to HSDT's ROE of -1.23%. Regarding short-term risk, BVS is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check HSDT's competition here
iCAD, Inc. (NASDAQ: ICAD)
BVS vs ICAD Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BVS's ROE is +0.28%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BVS is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BVS.Check ICAD's competition here
Owlet, Inc. (NYSE: OWLT)
BVS vs OWLT Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, OWLT has a market cap of 101.4M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while OWLT trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas OWLT's P/E ratio is -40.04. In terms of profitability, BVS's ROE is +0.28%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, BVS is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for BVS.Check OWLT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BVS vs HJLI Comparison August 2026
Bioventus Inc. (NASDAQ: BVS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BVS stands at 970.8M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BVS is priced at $14.29 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BVS currently has a P/E ratio of 18.86, whereas HJLI's P/E ratio is N/A. In terms of profitability, BVS's ROE is +0.28%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BVS is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BVS.Check HJLI's competition here